Hisamitsu Pharmaceutical Co., Inc. , headquartered in Saga and Tokyo, Japan is a pharmaceutical company that develops and markets prescription and over-the-counter drug products, especially external pain relieving products such as the transdermal patch. Hisamitsu has specialized in transdermal drug delivery system technology since the introduction of its original line of patches in 1903. Its Salonpas brand of products are exported to over fifty countries. Hisamitsu also manufactures the Mohrus and Mohrus-Tape line of external pain relief prescription products for the Japanese drug market. The company also manufactures internal medicines, eye drops for general application and the Lifecella Face Mask, a skin-care product. Hisamitsu has developed the only over-the-counter transdermal patches approved by the U.S Food and Drug Administration . Wikipedia.


Time filter

Source Type

Patent
Hisamitsu Pharmaceutical | Date: 2016-10-24

A method for producing a patch comprising a support layer and an adhesive agent layer comprises: a mixture preparation step of mixing asenapine or a pharmaceutically acceptable salt thereof with sodium acetate whose particle diameter D_(50 )at a cumulative volume of 50% in a particle diameter distribution is 40 to 1000 m, in such a manner that the sodium acetate and sodium diacetate generated from the sodium acetate have a particle diameter D_(50 )of 10 m or smaller, thereby obtaining a mixture containing the sodium diacetate and the asenapine or pharmaceutically acceptable salt; and an adhesive-agent-layer formation step of forming the adhesive agent layer comprising the sodium diacetate, the asenapine or pharmaceutically acceptable salt, and a pressure-sensitive adhesive base agent, by using an adhesive agent layer composition obtained by mixing the mixture with the pressure-sensitive adhesive base agent.


Patent
Hisamitsu Pharmaceutical | Date: 2017-01-04

The invention provides a gel patch comprising a support and an adhesive layer on the support, wherein the adhesive layer comprises 1.5 to 2.5 mass% of ketoprofen, 1.5 to 2.5 mass% of 4-tert-butyl-4-methoxydibenzoylmethane and 12 to 18 mass% of propylene glycol, based on the total mass of the adhesive layer.


Patent
Hisamitsu Pharmaceutical | Date: 2017-01-04

A microneedle sheet according to an embodiment includes a plurality of microneedles formed on a sheet generally along a principal surface of the sheet. The material of the microneedles is selected from among hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyvinyl alcohol, and a graft copolymer of polyvinyl alcohol and polyethylene glycol. The microneedles are raised from the principal surface by bending the sheet, and the raised microneedles pierce skin.


Patent
Hisamitsu Pharmaceutical | Date: 2017-03-09

A patch for administering asenapine includes a support layer, and an adhesive agent layer formed on the support layer and including an adhesive base agent and asenapine and/or a pharmaceutically acceptable salt thereof. The adhesive base agent has a content in a range of 10 to 90% by mass in the adhesive agent layer and includes a natural rubber, polyisobutylene, an alkyl vinyl ether(co)polymer, polyisoprene, polybutadiene, a styrene-butadiene copolymer, a styrene-isoprene copolymer, a styrene-isoprene-styrene block copolymer, or a combination thereof. When a content of the asenapine and/or pharmaceutically acceptable salt thereof in terms of free asenapine in the adhesive agent layer is 3.4 mg, an AUC_(2-120 )for a period starting from the time when the patch is brought into contact with a skin for 24 hours is 27,000 pghr/mL or more, and an AUC_(2-120 )of an asenapine metabolite is 20% or less of the AUC_(2-120 )of the free asenapine.


Patent
Hisamitsu Pharmaceutical | Date: 2016-04-13

An oral cavity patch comprising: a drug layer and an adhesive layer, wherein the drug layer comprises a drug-release-controlling agent consisting or at least one selected from the group consisting of a hydroxyalkyl alkyl cellulose, hydroxypropyl cellulose, a sodium carboxyalkyl cellulose, ethyl cellulose, hydrogenated castor oil, and a sucrose fatty acid ester.


Patent
Hisamitsu Pharmaceutical | Date: 2016-07-13

A microneedle sheet in an embodiment of the present invention includes a plurality of microneedles formed on a sheet generally along a principal surface of the sheet. The microneedles are configured to rise from the principal surface when the sheet is bent, and the raised microneedles pierce skin. At least some of the microneedles each have a region for exposing a tear formed in the skin in a needle inserted state.


Patent
Hisamitsu Pharmaceutical | Date: 2016-04-13

The present invention provides a system for manufacturing a therapeutic microneedle configured to regulate an air environment within a coating chamber for manufacturing a therapeutic microneedle by coating a microneedle with a coating liquid containing a drug, the system for manufacturing a therapeutic microneedle comprising an air compressor, a humidity regulator configured to regulate humidity of air supplied from the air compressor, and an air filter configured to eliminate microorganisms from air to be supplied to the inside of the coating chamber.


Patent
Hisamitsu Pharmaceutical | Date: 2016-06-29

A gel patch comprising a plaster layer on a support, the plaster layer comprising a mixture of at least a neutralized polyacrylic acid, a poly(methyl acrylate/2-ethylhexyl acrylate) emulsion, and water, wherein the poly(methyl acrylate/2-ethylhexyl acrylate) emulsion is an emulsion having an evaporation residue of 57 to 61% by heating at or above the boiling point of the medium and is present in an amount of at least 2.5 times and preferably at least 3 times the mass of the neutralized polyacrylic acid.


Patent
Hisamitsu Pharmaceutical | Date: 2016-10-19

A cover material-equipped patch comprising:a patch; anda cover material, whereinthe patch comprises a support layer and a drug reservoir layer which is stacked on one surface of the support layer and which contains a drug and a drug reservoir base agent,the cover material comprises a cover layer and an adhesive layer which is stacked on one surface of the cover layer and which contains an adhesive base agent,the patch and the cover material are arranged in such a manner that the adhesive layer is stacked on another surface of the support layer, anda solubility parameter (SPa) of the drug, a solubility parameter (SPb) of the drug reservoir base agent, and a solubility parameter (SPc) of the adhesive base agent simultaneously satisfy conditions represented by the following formulae (1) to (3):


Patent
Hisamitsu Pharmaceutical | Date: 2016-09-07

An adjuvant composition of the present invention contains lauryl alcohol and propylene glycol. Contents of the lauryl alcohol and the propylene glycol are 0.5 to 25% by mass and 8.0 to 99.5% by mass, relative to the total mass of the adjuvant composition, respectively. The lauryl alcohol is dissolved, and the adjuvant composition is used for transdermal or transmucosal administration.

Loading Hisamitsu Pharmaceutical collaborators
Loading Hisamitsu Pharmaceutical collaborators